Beta-Caryophyllene / P21 Cancer Research Results

BCP, Beta-Caryophyllene: Click to Expand ⟱
Features:

β-Caryophyllene is a dietary sesquiterpene and CB2 agonist with preclinical anticancer evidence, including apoptosis induction, reduced proliferation, anti-angiogenesis, reduced invasion/migration, and chemo/radio-sensitization. Evidence is promising but remains mainly in-vitro and animal-based; clinical cancer validation is lacking.
-naturally occurring sesquiterpene found in many plant essential oils: black pepper, clove oil ...

Beta-Caryophyllene — β-Caryophyllene is a plant-derived bicyclic sesquiterpene hydrocarbon and dietary cannabinoid with selective functional agonism at cannabinoid receptor type 2. It is formally classified as a natural sesquiterpene terpene, food flavoring compound, and investigational phytochemical adjunct rather than an approved anticancer drug. Standard abbreviations include BCP, β-CP, and sometimes trans-caryophyllene. It occurs in multiple essential oils, especially black pepper, clove, copaiba, oregano, hops, rosemary, and Cannabis sativa chemotypes, but its database identity should be the purified compound rather than a whole-oil product.

Primary mechanisms (ranked):

  1. CB2-centered anti-inflammatory and immunomodulatory signaling, with low CB1 activity and therefore no intrinsic THC-like psychoactive classification.
  2. Suppression of pro-survival oncogenic signaling, especially PI3K/Akt/mTOR, STAT3, NF-κB, and related proliferation or survival pathways in cancer models.
  3. Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, caspase activation, mitochondrial stress, and cell-cycle arrest in several cancer cell lines.
  4. Anti-angiogenic and anti-migratory activity, including inhibition of endothelial migration, tube formation, VEGF-linked responses, EMT, invasion, and metastasis-associated phenotypes.
  5. Chemosensitization, mainly preclinical, reported with cisplatin and other cytotoxic or targeted agents; mechanism appears context-dependent and partly linked to apoptosis and resistance-pathway modulation.
  6. Radiosensitization, currently preliminary and model-dependent, with recent colorectal cancer cell evidence involving PPARγ-mediated apoptosis.
  7. ROS/NRF2 modulation is secondary and context-dependent: BCP can promote oxidative stress in cancer-cell apoptosis models, while in normal injury models it more often shows cytoprotective antioxidant and NRF2-linked effects.

Bioavailability / PK relevance: BCP is highly lipophilic and formulation-sensitive; oral exposure is limited and variable with conventional dosing, while self-emulsifying lipid formulations can substantially improve human systemic exposure. PK relevance is high because many in-vitro anticancer concentrations are unlikely to be reproduced by normal dietary intake.

Delivery constraints: The key delivery constraints are volatility, hydrophobicity, oxidation/stability, low aqueous solubility, food-matrix dependence, and the likely need for lipid, nanoemulsion, SEDDS, or other formulation strategies if systemic pharmacology is the goal.

In-vitro vs systemic exposure relevance: Most anticancer assays use micromolar-to-high-micromolar or µg/mL concentrations; these should be interpreted cautiously because common in-vitro levels likely exceed exposures achievable from culinary intake. Formulated oral BCP may improve exposure, but clinical anticancer target engagement has not been established.

Clinical evidence status: Preclinical oncology evidence is moderate and spans cell, endothelial, and animal models; human evidence is small and mostly non-oncology or PK-focused. No validated clinical cancer efficacy evidence was found. Best database status is preclinical / investigational adjunct, with possible chemosensitizer and anti-angiogenic tags marked as preclinical.

Beta-Caryophyllene Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 CB2 receptor signaling CB2 engagement may shift inflammatory and survival signaling ↓ (context-dependent) CB2-mediated inflammation ↓ with low CB1 psychoactivity R/G Anti-inflammatory and immunomodulatory signaling Core pharmacologic identity of BCP; direct anticancer dependence on CB2 varies by model.
2 PI3K Akt mTOR STAT3 survival signaling PI3K/Akt/mTOR ↓; STAT3 ↓; proliferation ↓; survival ↓ Usually cytoprotective or neutral at lower exposure (context-dependent) R/G Growth suppression and apoptosis sensitization Central anticancer axis across bladder, ovarian, lung, and other cell models; not yet clinically validated.
3 Mitochondrial apoptosis Bax ↑; Bcl-2 ↓; caspase-3 ↑; mitochondrial stress ↑; apoptosis ↑ In injury models, mitochondrial dysfunction often ↓ G Intrinsic apoptotic cell death Strong recurring preclinical mechanism; cancer selectivity depends on dose and model.
4 Angiogenesis and endothelial migration VEGF-linked angiogenesis ↓; invasion ↓; migration ↓ Endothelial migration and tube formation ↓ (model-dependent) G Anti-angiogenic and anti-metastatic pressure Important for colorectal xenograft and endothelial assay interpretation; may be therapeutically relevant but exposure-limited.
5 NF-κB inflammatory signaling NF-κB-linked survival and cytokine tone ↓ (context-dependent) Inflammatory cytokine signaling ↓ R/G Inflammation-linked tumor support reduction More robust as an anti-inflammatory mechanism than as a standalone cancer-killing mechanism.
6 ROS and mitochondrial oxidative stress ROS ↑ can contribute to apoptosis (high concentration only) Oxidative stress ↓ in many toxic injury models R/G Context-dependent redox modulation antioxidant or pro-oxidant; direction depends on cell type, injury context, and concentration.
7 NRF2 cytoprotection ↔ or context-dependent; may be undesirable if it protects malignant cells NRF2/HO-1/NQO1 ↑ in injury-protection models G Secondary antioxidant-response modulation NRF2 is not a core anticancer mechanism for BCP; tag as secondary/contextual rather than primary.
8 Chemosensitization Cisplatin response ↑; apoptosis ↑; resistance signaling ↓ (model-dependent) Normal-cell toxicity data are insufficient for oncology combinations G Adjunct sensitization Preclinical evidence supports a sensitizer hypothesis, but there is no clinical cancer validation.
9 Radiosensitization Radiation response ↑ in colorectal cancer cells (model-dependent) Normal-tissue radioprotection versus radiosensitization is unresolved G Potential radiation adjunct Recent evidence is early and should be tagged as preliminary, not established.
10 Glycolysis and HIF-1α ↔ limited direct oncology evidence ↔ not a primary established axis G Not a core mechanism Do not add strong HIF-1α or glycolysis tags unless future product-specific cancer evidence supports them.
11 Clinical Translation Constraint Effective in-vitro exposure may exceed practical dietary exposure Food-use safety does not establish therapeutic-dose safety G PK and evidence limitation Key constraints are bioavailability, formulation, dose, tissue exposure, cancer-type heterogeneity, and lack of oncology trials.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
P21, P21/CDKN1A: Click to Expand ⟱
Source:
Type: Proapototic
cyclin-dependent kinase inhibitor p21 (also known as p21 WAF1/Cip1) promotes cell cycle arrest in response to many stimuli.
P21 is a cyclin-dependent kinase inhibitor that plays a crucial role in regulating the cell cycle. It is encoded by the CDKN1A gene and is a key player in the cellular response to stress, including DNA damage.
P21 is often considered a tumor suppressor because its expression is upregulated in response to p53 activation, a well-known tumor suppressor protein. When DNA damage occurs, p53 can activate the transcription of the CDKN1A gene, leading to increased levels of P21, which helps prevent the proliferation of damaged cells.
In many cancers, the p53 pathway is disrupted, leading to decreased levels of P21. p21 is a apoptotic marker protein.
Cell cycle arrest gene p21
Field Suggested Entry
Target CDKN1A / p21 / p21Cip1/Waf1
Full Name Cyclin-dependent kinase inhibitor 1A
Target Class CIP/KIP-family cyclin-dependent kinase inhibitor
Main Binding Partners CDK2, CDK1, CDK4/6, cyclin complexes, PCNA
Primary Biology p53-mediated cell-cycle arrest, DNA damage response, senescence, differentiation, CDK inhibition, RB/E2F pathway suppression, apoptosis regulation
Cancer Relevance High but context-dependent: p21 can suppress tumor growth through cell-cycle arrest and senescence, but can also support apoptosis resistance, senescent-cell survival, and therapy resistance in some tumors
AD Relevance Medium: indirect relevance through neuronal cell-cycle re-entry, senescence, p53 stress signaling, and aging-related cell-cycle dysregulation
Therapeutic Direction Context-dependent. Restore/activate p21 for tumor-suppressive arrest where appropriate; inhibit or bypass p21 where it promotes apoptosis resistance, senescent-cell survival, or treatment resistance.


Scientific Papers found: Click to Expand⟱
6496- BCP,    β-Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models
- vitro+vivo, CRC, HCT116 - in-vitro, Nor, HUVECs
angioG↓, VEGF↓, TumVol↓, Apoptosis↑, HSPD1 / HSP60↓, HTRA↓, survivin↓, XIAP↓, P21↑, *toxicity↓, *neuroP↑, *ROS↓, *COX2↓, *Inflam↓, *cardioP↑, AntiCan↑, ChemoSen↑, ROS↑, MMP↑, Bax:Bcl2↑, TumCG↓,
6497- BCP,  Cisplatin,    Beta-Caryophyllene Enhances the Anti-Tumor Activity of Cisplatin in Lung Cancer Cell Lines through Regulating Cell Cycle and Apoptosis Signaling Molecules
- in-vitro, Lung, NA
TumCG↓, TumCP↓, Apoptosis↑, toxicity↓, ChemoSen↑, P21↑, Bcl-xL↑, Bcl-2↓, EMT↓, E-cadherin↑, eff↑, MMP↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

HSPD1 / HSP60↓, 1,   HTRA↓, 1,  

Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,   MMP↑, 1,   XIAP↓, 1,  

Cell Death ⓘ

Apoptosis↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Bcl-xL↑, 1,   survivin↓, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   TumCG↓, 2,  

Migration ⓘ

E-cadherin↑, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,   eff↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   toxicity↓, 1,   TumVol↓, 1,  
Total Targets: 23

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Inflam↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: P21, P21/CDKN1A
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:401  Target#:234  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page